Vitamin K2 and D3 Synergize to Kill Triple-Negative Breast Cancer Cells

Vitamin K2 and D3 Synergies to Kill Triple-Negative Breast Cancer Cells.

Vitamin D3 and vitamin K2 are commonly known for their roles in bone health and calcium metabolism, but researchers are also studying how these vitamins may affect the growth and survival of cancer cells. 

INVEST IN YOUR HEALTH AND SAVE BIG NOW!

Buy One Get One Free. Discount Code:D50

Product Link: https://lookingvibrant.com/products/raw-d3-vegetarian-k2

One area of interest is triple-negative breast cancer (TNBC), an aggressive form of breast cancer with fewer targeted treatment options. A 2023 study published in the Journal of Steroid Biochemistry and Molecular Biology tested vitamin K2 (MK-4) together with active vitamin D3 (calcitriol) in three triple-negative breast cancer cell lines. The combination significantly reduced the number of living cancer cells more than either treatment alone in 2 of the 3 cell lines and stopped all three cell types in the G0/G1 stage of the cell cycle, limiting their ability to move toward division.

K2 also increased vitamin D receptor (VDR) levels in one cell line, potentially making those cells more responsive to vitamin D. PMID: 37030416 - Synergy, not additive: MK-4 + calcitriol = combo index <1 in 2/3 TNBC lines (HCC38, MDA-MB-453).

Not just "more", it's synergistic kill + G0/G1 arrest - Mechanism: K2 ↑ VDR expression in HCC38 → makes cells _listen_ to D3 again. TNBC often silences VDR — K2 reverses that - Important limit: This is *in vitro* (3 cell lines, not patients). Doses = supraphysiological calcitriol — would cause hypercalcemia in humans.

Translation needs analogs or targeted delivery Why K2+D3 for TNBC? TNBC = no ER/PR/HER2 targets.

VDR is a backdoor. K2 (MK-4) turns up the volume on VDR, D3 pushes stop button on cell cycle.

Combo alone. Caveat: cells in dish ≠ patients. But opens low-toxicity adjunct hypothesis. Source: PMID 37030416 DOI: 10.1016/j.jsbmb.2023.106281— same paper, easy for MDs to find.